Log In
BCIQ
Print this Print this
 

PAS-YNSalpha8

  Manage Alerts
Collapse Summary General Information
Company XL-protein GmbH
DescriptionPASylated interferon variant YNSalpha8
Molecular Target
Mechanism of Action 
Therapeutic ModalityBiologic: Protein
Latest Stage of DevelopmentPreclinical
Standard IndicationInflammatory disease
Indication DetailsTreat inflammatory diseases of central nervous system
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

0

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

10/21/2014

Undisclosed

Undisclosed

Undisclosed

Get a free BioCentury trial today